Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report.

ABSTRACT:

Background

Antiretroviral drugs are essential for preventing mother-to-child transmission (MTCT) of HIV in HIV-infected pregnant women. However, ART treatment for HIV-infected pregnant women with multidrug resistance remains a major challenge. Effective and safe ART regimens for preventing MTCT should be tailored to this special population. Albuvirtide (ABT) is along-acting fusion inhibitor with proven efficacy and safety in adults with multidrug-resistant HIV. Herein, for the first time, we report the use of an ABT-based ART regimen in pregnant women infected with multidrug-resistant HIV.

Case presentation

A 25-year-old female HIV patient with an estimated gestational age of 14 weeks who received the TDF + 3TC + EFV regimen. The tests revealed an HIV- RNA concentration of 1

SUBMITTER: Li N 

PROVIDER: S-EPMC11760105 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature